Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
LCDD
MCID: LGH004
MIFTS: 47

Light Chain Deposition Disease (LCDD)

Categories: Blood diseases, Immune diseases, Nephrological diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Light Chain Deposition Disease

About this section

MalaCards integrated aliases for Light Chain Deposition Disease:

Name: Light Chain Deposition Disease 54 60
Light-Chain Deposition Disease 54
Light Chain Disease 74
Lcdd 60

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Nephrological diseases Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 35
Orphanet: 60  
Rare renal diseases
Rare haematological diseases


External Ids:

ICD10 via Orphanet 35 D89.8
UMLS via Orphanet 75 C0238239
Orphanet 60 ORPHA93558
UMLS 74 C0238239
Sources

Summaries for Light Chain Deposition Disease

About this section
NIH Rare Diseases : 54 Light chain deposition disease (LCDD) is a rare condition characterized by the deposition of specific proteins (monoclonal light chains) in the kidneys and other organs. Light chains are used to make antibodies that the body needs to fight infection. People with LCDD make too many light chains, which get deposited in many body tissues. While LCDD can occur in any organ, the kidneys are always involved. Signs and symptoms of LCDD may include protein in the urine; decreased kidney function; and/or nephrotic syndrome. Rarely, a person with LCDD may have symptoms from cardiac (heart) or liver involvement. The underlying cause of LCDD is unknown. It is often associated with multiple myeloma. LCDD may progress to multiple myeloma, or it may be present with multiple myeloma when it is first diagnosed. The goal of treating LCDD is to slow the production of light chains and their damage to organs. Treatment may include chemotherapy with a drug called Bortezomib; autologous stem cell transplantation; immunomodulatory drugs; and/or kidney transplant. If untreated, end-stage renal disease occurs in 70% of cases.

MalaCards based summary : Light Chain Deposition Disease, also known as light-chain deposition disease, is related to lacrimal duct defect and amyloidosis. An important gene associated with Light Chain Deposition Disease is IGKC (Immunoglobulin Kappa Constant), and among its related pathways/superpathways are Integrin Pathway and Degradation of the extracellular matrix. The drugs Bortezomib and Melphalan have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia : 77 Light chain deposition disease (LCDD) is a rare blood cell disease which is characterized by deposition... more...

Sources

Related Diseases for Light Chain Deposition Disease

About this section

Diseases related to Light Chain Deposition Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)
# Related Disease Score Top Affiliating Genes
1 lacrimal duct defect 11.8
2 amyloidosis 10.5
3 myeloma, multiple 10.4
4 fibromatosis, gingival, 1 10.3 MMP1 MMP2
5 multicentric osteolysis, nodulosis, and arthropathy 10.2 MMP14 MMP2
6 winchester syndrome 10.2 MMP14 MMP2
7 conjunctivochalasis 10.2 MMP1 MMP2
8 mid-dermal elastolysis 10.2 MMP12 MMP7
9 lymphoma 10.2
10 chronic actinic dermatitis 10.2 MMP1 MMP9
11 chromoblastomycosis 10.2 MMP1 MMP9
12 extracranial arteriovenous malformation 10.2 MMP2 MMP9
13 villous adenocarcinoma 10.2 MMP2 MMP9
14 lentigo maligna melanoma 10.2 MMP2 MMP9
15 psammomatous meningioma 10.2 MMP2 MMP9
16 acute transverse myelitis 10.1 MMP2 MMP9
17 transverse myelitis 10.1 MMP2 MMP9
18 ischemic colitis 10.1 MMP2 MMP9
19 pelvic organ prolapse 10.1 MMP1 MMP9
20 conjunctival nevus 10.1 MMP2 MMP9
21 parotitis 10.1 MMP2 MMP9
22 collagenous colitis 10.1 MMP1 MMP9
23 corneal ulcer 10.1 MMP2 MMP9
24 brain glioblastoma multiforme 10.1 MMP7 MMP9
25 aortic aneurysm, familial thoracic 1 10.1 MMP1 MMP2
26 lymph node disease 10.1 MMP1 MMP14
27 al amyloidosis 10.1
28 chronic venous insufficiency 10.1 MMP1 MMP9
29 pediatric multiple sclerosis 10.1 MMP7 MMP9
30 nasal cavity squamous cell carcinoma 10.1 MMP2 MMP9
31 venous insufficiency 10.1 MMP1 MMP9
32 keloids 10.1 MMP1 TNC
33 immunotactoid glomerulopathy 10.1
34 lymphangioleiomyomatosis 10.1 MMP1 MMP14 MMP2
35 coronary artery aneurysm 10.1 MMP1 MMP12 MMP7
36 malignant giant cell tumor of soft parts 10.0 ACTC1 CD68
37 pulmonary emphysema 10.0 MMP1 MMP12 MMP9
38 sialadenitis 10.0 MMP2 TNC
39 newcastle disease 10.0 MMP2 MMP9
40 infantile liver failure syndrome 1 10.0
41 portal hypertension 10.0
42 nephrotic syndrome 10.0
43 restrictive cardiomyopathy 10.0
44 light and heavy chain deposition disease 10.0
45 heavy chain deposition disease 10.0
46 laryngeal disease 10.0 MMP2 MMP9
47 cryptogenic organizing pneumonia 10.0 MMP9 TNC
48 ischemic fasciitis 10.0 ACTC1 CD68
49 odontogenic myxoma 10.0 MMP1 MMP2 MMP9
50 pulmonary disease, chronic obstructive 10.0 MMP1 MMP12 MMP9

Graphical network of the top 20 diseases related to Light Chain Deposition Disease:



Diseases related to Light Chain Deposition Disease
Sources

Symptoms & Phenotypes for Light Chain Deposition Disease

About this section

MGI Mouse Phenotypes related to Light Chain Deposition Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.56 ACTC1 MMP1 MMP12 MMP14 MMP2 MMP7
2 immune system MP:0005387 9.17 CD68 MMP1 MMP12 MMP14 MMP2 MMP7
Sources

Drugs & Therapeutics for Light Chain Deposition Disease

About this section

Drugs for Light Chain Deposition Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bortezomib Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 179324-69-7 387447 93860
2
Melphalan Approved Phase 3,Phase 2,Not Applicable 148-82-3 460612 4053
3
Mechlorethamine Approved, Investigational Phase 3,Phase 2 51-75-2 4033
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
6
Lenalidomide Approved Phase 3 191732-72-6 216326
7
Prednisone Approved, Vet_approved Phase 3,Phase 2 53-03-2 5865
8 Daratumumab Approved Phase 3 945721-28-8
9 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
10 phenylalanine Phase 3,Phase 2
11 Anti-Inflammatory Agents Phase 3,Phase 2,Phase 1,Not Applicable
12 Antineoplastic Agents, Alkylating Phase 3,Phase 2
13 HIV Protease Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
14 Hormones Phase 3,Phase 2,Phase 1,Not Applicable
15
protease inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
16 Autonomic Agents Phase 3,Phase 2,Phase 1,Not Applicable
17 BB 1101 Phase 3,Phase 2,Phase 1,Not Applicable
18 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
19 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1,Not Applicable
20 Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
21 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
22 Alkylating Agents Phase 3,Phase 2
23 Antiemetics Phase 3,Phase 2,Phase 1,Not Applicable
24 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
25 glucocorticoids Phase 3,Phase 2,Phase 1,Not Applicable
26 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
27 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
28 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
29 Antibodies Phase 3,Phase 2,Not Applicable
30 Immunoglobulins Phase 3,Phase 2,Not Applicable
31 Antibodies, Monoclonal Phase 3
32
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
33
Cisplatin Approved Phase 2 15663-27-1 441203 84093 2767
34
Etoposide Approved Phase 2 33419-42-0 36462
35
Cyclophosphamide Approved, Investigational Phase 2,Not Applicable 6055-19-2, 50-18-0 2907
36
Lenograstim Approved, Investigational Phase 2 135968-09-1
37
Doxil Approved June 1999 Phase 2 31703
38 Interferon-alpha Phase 2
39 Anti-Infective Agents Phase 2,Phase 1
40 interferons Phase 2
41 Antiviral Agents Phase 2
42 Interferon alpha-2 Phase 2
43 Dexamethasone 21-phosphate Phase 2
44 Antineoplastic Agents, Phytogenic Phase 2
45 Antirheumatic Agents Phase 2
46 Topoisomerase Inhibitors Phase 2
47 Antibiotics, Antitubercular Phase 2
48 Anti-Bacterial Agents Phase 2,Phase 1
49 Etoposide phosphate Phase 2
50 Paraproteins Phase 2,Not Applicable

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Completed NCT01078454 Phase 3 melphalan;dexamethasone;bortezomib
2 Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Completed NCT01109004 Phase 3 Lenalidomide;lenalidomide, bortezomib and dexamethasone;Lenalidomide
3 Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Active, not recruiting NCT01169337 Phase 3 Lenalidomide
4 A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma Active, not recruiting NCT02195479 Phase 3 Velcade;Melphalan;Prednisone;Daratumumab;Dexamethasone
5 S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis Completed NCT00002849 Phase 2 dexamethasone
6 Bortezomib With Melphalan and Prednisone for Multiple Myeloma Completed NCT00734149 Phase 2 Bortezomib;Melphalan;Prednisone
7 Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease Active, not recruiting NCT00520767 Phase 2 bortezomib;dexamethasone;melphalan
8 Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma Active, not recruiting NCT01849783 Phase 2 dexamethasone;cisplatin;doxorubicin;cyclophosphamide;etoposide;bortezomib;thalidomide;melphalan
9 HD Melphalan and SCT in Patients With IGDD or LCDD Terminated NCT00681044 Phase 2 melphalan
10 Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma Completed NCT01533194 Phase 1
11 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1 sunitinib malate
12 First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD Active, not recruiting NCT01728259 Phase 1 pomalidomide;bortezomib;dexamethasone
13 Rifaximin in Patients With Monoclonal Gammopathy Not yet recruiting NCT03820817 Phase 1 Rifaximin
14 Registry for Adults With Plasma Cell Disorders (PCD's) Recruiting NCT03717844
15 Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis Active, not recruiting NCT01383759 Not Applicable Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
16 Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects Terminated NCT01018927

Search NIH Clinical Center for Light Chain Deposition Disease

Sources

Genetic Tests for Light Chain Deposition Disease

About this section
Sources

Anatomical Context for Light Chain Deposition Disease

About this section

MalaCards organs/tissues related to Light Chain Deposition Disease:

42
Kidney, Heart, Liver, B Cells, Skin, Brain, Spleen
Sources

Publications for Light Chain Deposition Disease

About this section

Articles related to Light Chain Deposition Disease:

(show top 50) (show all 187)
# Title Authors Year
1
Light Chain Deposition Disease with Bullous Skin Lesions Mimicking Atypical Bullous Pemphigoid. ( 29135016 )
2018
2
Successful treatment of nephrotic syndrome induced by lambda light chain deposition disease using lenalidomide: A case report andA review of the literaturea8c. ( 29393843 )
2018
3
Light Chain Deposition Disease Associated With Multiple Myeloma Developing in Late Pregnancy. ( 29507277 )
2018
4
Acquired Fanconi syndrome secondary to light chain deposition disease associated with monoclonal gammopathy of renal significance: A case report. ( 30200082 )
2018
5
Unmasking and successful management of light chain deposition disease of kidney in pregnancy: a complex case, mirroring the complex needs of pregnancy with kidney disease in India. ( 30187379 )
2018
6
Lenalidomide as a Beneficial Treatment Option for Renal Impairment Caused by Light Chain Deposition Disease: A Case Series. ( 30101913 )
2018
7
Primary idiopathic CNS non-amyloidogenic light chain deposition disease complicated by treatment-resistant focal seizure disorder. ( 30424969 )
2018
8
Light-Chain Deposition Disease Presenting with Spontaneous Splenic Rupture. ( 30756004 )
2018
9
Detection and Treatment of Monoclonal Gammopathy of Renal Significance With Progression to Light Chain Deposition Disease. ( 28809601 )
2017
10
Primary CNS Nonamyloidogenic Light Chain Deposition Disease: Case Report and Brief Review. ( 28669250 )
2017
11
Primary Central Nervous System Lymphoma With Light Chain Deposition Disease (Aggregoma). ( 29280764 )
2017
12
Light Chain Deposition Disease Diagnosed with Laser Micro-dissection, Liquid Chromatography, and Tandem Mass Spectrometry of Nodular Glomerular Lesions. ( 28050001 )
2017
13
Cardiac light-chain deposition disease relapsing in the transplanted heart. ( 28562083 )
2017
14
Cutaneous Light Chain Deposition Disease: A Report of 2 Cases and Review of the Literature. ( 28953013 )
2017
15
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. ( 28383130 )
2017
16
Light-Chain Deposition Disease with Prominent Hepatic Involvement. ( 30755931 )
2017
17
Treatment of idiopathic light chain deposition disease: complete remission with bortezomib and dexamethasone. ( 28001187 )
2016
18
Surgical Management of Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma Associated With Light-Chain Deposition Disease. ( 27211983 )
2016
19
Spontaneous splenic rupture in a patient with light-chain deposition disease undergoing autologous peripheral blood stem cell transplantation. ( 27384856 )
2016
20
A Case of Cardiac Light Chain Deposition Disease in a Patient with Solitary Plasmacytoma. ( 26988342 )
2016
21
Five Sequential Evaluations of Renal Histology in a Patient with Light Chain Deposition Disease. ( 27746438 )
2016
22
Nodular pulmonary light chain deposition disease. ( 27306574 )
2016
23
Clinicopathological characteristics and outcomes of light chain deposition disease: an analysis of 48 patients in a single Chinese center. ( 27056200 )
2016
24
Can We Cure Light Chain Deposition Disease of the Kidneys?-A Review and Case Report of a Patient Treated With a Triple Transplant Approach. ( 27101986 )
2016
25
Animal Models of Light Chain Deposition Disease Provide a Better Understanding of Nodular Glomerulosclerosis. ( 26794829 )
2016
26
Intracystic hemorrhage in a patient with pulmonary cystic disorder related to light-chain deposition disease. ( 27756655 )
2016
27
Light Chain Deposition Disease After Kidney Transplantation With Long Graft Survival: Case Report. ( 26915878 )
2016
28
ATYPICAL MACULOPATHY IN A PATIENT WITH LIGHT CHAIN DEPOSITION DISEASE MIMICKING ADVANCED GEOGRAPHIC ATROPHY. ( 26934302 )
2016
29
Unusual case of light chain deposition disease kappa restricted in a case of multiple myeloma. ( 27728483 )
2016
30
Nodular pulmonary light chain deposition disease: an entity associated with SjAPgren syndrome or marginal zone lymphoma. ( 26502747 )
2016
31
Treatment of Light Chain Deposition Disease Using Bortezomib-Based Regimen Followed by Thalidomide-Based Regimen in a Saudi Male. ( 28083151 )
2016
32
Light Chain Deposition Disease in an Older Adult Patient Successfully Treated with Long-term Administration of Bortezomib, Melphalan and Prednisone. ( 27181540 )
2016
33
OCULAR MANIFESTATIONS OF MONOCLONAL IMMUNOGLOBULIN LIGHT CHAIN DEPOSITION DISEASE. ( 27315323 )
2016
34
Bortezomib Based Chemotherapy for Light Chain Deposition Disease. ( 27762125 )
2016
35
A case of light chain deposition disease in kidney in a known case of multiple myeloma. ( 27728501 )
2016
36
Unusual Presentation of Light Chain Deposition Disease: A Case Report. ( 27437235 )
2016
37
ENHANCED DEPTH IMAGING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY FEATURES OF LIGHT CHAIN DEPOSITION DISEASE. ( 26398301 )
2015
38
Natural history and outcome of light chain deposition disease. ( 26392598 )
2015
39
Light-Chain Deposition Disease Successfully Treated with Bortezomib in an Elderly Patient: A Case Report and Review of the Literature. ( 26568005 )
2015
40
AJKD Atlas of Renal Pathology: Light Chain Deposition Disease. ( 26593321 )
2015
41
Clinical and Prognostic Differences among Patients with Light Chain Deposition Disease, Myeloma Cast Nephropathy and Both. ( 25860232 )
2015
42
Pulmonary light-chain deposition disease: CT and pathology findings in nine patients. ( 25659938 )
2015
43
Enlightening light chain deposition disease. ( 26705338 )
2015
44
Monoclonal gammopathy of renal significance with light-chain deposition disease diagnosed postrenal transplant: a diagnostic and therapeutic challenge. ( 25441103 )
2015
45
Blood stem cell transplantation to treat cystic lung light chain deposition disease. ( 26160867 )
2015
46
Nonamyloid tumoral light-chain-deposition disease (aggregoma) of the paraspinal region. ( 26253133 )
2015
47
Education and imaging. Hepatobiliary and Pancreatic: Portal hypertension due to hepatic light chain deposition disease. ( 24832781 )
2014
48
Osteolytic femoral lesion detected by sonography in a case of light chain deposition disease. ( 24449208 )
2014
49
Isolated intracerebral light chain deposition disease: novel imaging and pathologic findings. ( 25084689 )
2014
50
Light chain deposition disease without glomerular proteinuria: a diagnostic challenge for the nephrologist. ( 24619059 )
2014
Sources

Variations for Light Chain Deposition Disease

About this section
Sources

Expression for Light Chain Deposition Disease

About this section
Search GEO for disease gene expression data for Light Chain Deposition Disease.
Sources

Pathways for Light Chain Deposition Disease

About this section

Pathways related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

(show all 24)
# Super pathways Score Top Affiliating Genes
1
Integrin Pathway 65
Show member pathways
 13.15 MMP1 MMP12 MMP2 MMP7 MMP9 TNC
2
Degradation of the extracellular matrix 67
Show member pathways
 12.45 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
3
G-protein signaling Regulation of p38 and JNK signaling mediated by G-proteins 23
Show member pathways
 11.98 MMP1 MMP12 MMP2 MMP7 MMP9 TNC
4
TGF-beta Signaling Pathway (WikiPathways) 1
11.87 MMP1 MMP12 TNC
5
Microglia Activation During Neuroinflammation: Overview 66
Show member pathways
 11.86 MMP2 MMP7 MMP9 TNC
6
Colorectal Cancer Metastasis 65
11.85 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
7
Adhesion 4
11.82 MMP14 MMP2 MMP9
8
Interleukin-4 and 13 signaling 67
11.78 MMP1 MMP2 MMP9
9
Angiogenesis (CST) 4
11.62 MMP2 MMP7 MMP9 TNC
10
Bladder cancer 38 1
11.56 MMP1 MMP2 MMP9
11
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.49 MMP1 MMP2 MMP9
12
AGE/RAGE pathway 1
11.44 MMP14 MMP2 MMP7 MMP9
13
Matrix Metalloproteinases 1
Show member pathways
 11.43 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
14
amb2 Integrin signaling 1
11.3 MMP2 MMP9
15
Osteopontin-mediated events 1
Show member pathways
 11.26 MMP2 MMP9
16
Cell adhesion_Cell-matrix glycoconjugates 23
11.26 MMP1 MMP9 TNC
17
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.18 MMP1 MMP2 MMP9
18
A-beta Pathways: Uptake and Degradation 66
11.11 MMP2 MMP9
19
Syndecan-4-mediated signaling events 1
11.09 MMP9 TNC
20
Plasma membrane estrogen receptor signaling 1
11.01 MMP2 MMP9
21
A-beta Pathways: Plaque Formation and APP Metabolism 66
10.95 MMP2 MMP9
22
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 67
10.9 MMP1 MMP2
23
Cell adhesion_ECM remodeling 23
10.89 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
24
Syndecan-1-mediated signaling events 1
10.84 MMP1 MMP7 MMP9
Sources

GO Terms for Light Chain Deposition Disease

About this section

Cellular components related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.76 IGKC IGKV1-5 MMP1 MMP12 MMP2 MMP7
2 extracellular space GO:0005615 9.61 ACTC1 IGKC IGKV1-5 MMP12 MMP14 MMP2
3 blood microparticle GO:0072562 9.43 ACTC1 IGKC IGKV1-5
4 extracellular matrix GO:0031012 9.17 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9

Biological processes related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.7 IGKV1-5 MMP1 MMP12 MMP14 MMP2 MMP7
2 leukocyte migration GO:0050900 9.62 IGKC IGKV1-5 MMP1 MMP9
3 cellular protein metabolic process GO:0044267 9.58 MMP1 MMP2 TNC
4 response to hypoxia GO:0001666 9.54 MMP12 MMP14 MMP2
5 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.46 MMP2 MMP9
6 embryo implantation GO:0007566 9.43 MMP2 MMP9
7 endodermal cell differentiation GO:0035987 9.43 MMP14 MMP2 MMP9
8 extracellular matrix disassembly GO:0022617 9.43 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
9 collagen catabolic process GO:0030574 9.1 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9

Molecular functions related to Light Chain Deposition Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity GO:0016787 9.88 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
2 zinc ion binding GO:0008270 9.85 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
3 peptidase activity GO:0008233 9.73 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
4 metallopeptidase activity GO:0008237 9.63 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
5 endopeptidase activity GO:0004175 9.62 MMP1 MMP12 MMP14 MMP9
6 metalloendopeptidase activity GO:0004222 9.43 MMP1 MMP12 MMP14 MMP2 MMP7 MMP9
7 serine-type endopeptidase activity GO:0004252 9.17 IGKV1-5 MMP1 MMP12 MMP14 MMP2 MMP7
Sources

Sources for Light Chain Deposition Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....